Tarsus Pharmaceuticals (TARS) Stock Forecast, Price Target & Predictions
TARS Stock Forecast
Tarsus Pharmaceuticals stock forecast is as follows: an average price target of $61.00 (represents a 99.41% upside from TARS’s last price of $30.59) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
TARS Price Target
The average price target for Tarsus Pharmaceuticals (TARS) is $61.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $61.00 to $61.00. This represents a potential 99.41% upside from TARS's last price of $30.59.
TARS Analyst Ratings
According to 4 Wall Street analysts, Tarsus Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for TARS stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Tarsus Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 13, 2024 | Oren Livnat | H.C. Wainwright | $61.00 | $37.00 | 64.86% | 99.41% |
The latest Tarsus Pharmaceuticals stock forecast, released on May 13, 2024 by Oren Livnat from H.C. Wainwright, set a price target of $61.00, which represents a 64.86% increase from the stock price at the time of the forecast ($37.00), and a 99.41% increase from TARS last price ($30.59).
Tarsus Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $61.00 |
| Last Closing Price | $30.59 | $30.59 | $30.59 |
| Upside/Downside | -100.00% | -100.00% | 99.41% |
In the current month, the average price target of Tarsus Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Tarsus Pharmaceuticals's last price of $30.59. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 10, 2024 | Barclays | Overweight | Overweight | Hold |
| May 09, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Feb 28, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jul 25, 2023 | William Blair | Outperform | Outperform | Hold |
Tarsus Pharmaceuticals's last stock rating was published by H.C. Wainwright on May 13, 2024. The company gave TARS a "Buy" rating, the same as its previous rate.
Tarsus Pharmaceuticals Financial Forecast
Tarsus Pharmaceuticals Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $13.08M | $1.87M | $2.50M | $10.00M | - | - | $539.00K | $338.00K | $1.24M | $22.02M | $33.43M |
| Avg Forecast | $178.69M | $158.69M | $139.37M | $127.92M | $83.92M | $75.10M | $67.07M | $59.76M | $52.11M | $43.61M | $32.33M | $17.89M | $5.47M | $399.56K | $3.33M | $10.00M | $3.50M | $11.25M | $5.20M | $1.87M | $5.33M | $4.53M | $3.33M |
| High Forecast | $187.26M | $166.31M | $146.06M | $134.05M | $87.94M | $78.70M | $70.29M | $62.63M | $54.61M | $46.37M | $33.88M | $18.75M | $7.11M | $418.72K | $3.49M | $10.48M | $3.67M | $11.25M | $6.12M | $2.20M | $6.28M | $5.34M | $3.92M |
| Low Forecast | $162.26M | $144.10M | $126.55M | $116.15M | $76.20M | $68.19M | $60.91M | $54.26M | $47.32M | $40.26M | $29.36M | $16.25M | $2.54M | $362.81K | $3.03M | $9.08M | $3.18M | $11.25M | $4.43M | $1.59M | $4.54M | $3.86M | $2.84M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 3 | 3 | 1 | - | 2 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 2.39% | 4.68% | 0.75% | 1.00% | - | - | 0.10% | 0.18% | 0.23% | 4.86% | 10.03% |
Tarsus Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 4 analysts is $17.89M, with a low forecast of $16.25M, and a high forecast of $18.75M. TARS's average Quarter revenue forecast represents a 36.84% increase compared to the company's last Quarter revenue of $13.08M (Dec 23).
Tarsus Pharmaceuticals EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 3 | 3 | 1 | - | 2 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-44.45M | $-40.94M | $-22.65M | $-12.98M | $-21.76M | - | $-19.04M | $-14.76M | $-15.96M | $6.50M | $10.80M |
| Avg Forecast | $-6.63M | $-5.89M | $-5.17M | $-4.75M | $-3.11M | $-2.79M | $-2.49M | $-2.22M | $-1.93M | $-1.62M | $-1.20M | $-663.89K | $-203.00K | $-14.82K | $-123.67K | $-371.02K | $-12.39M | $-417.39K | $-17.40M | $-69.23K | $-13.25M | $-168.19K | $-123.67K |
| High Forecast | $-6.02M | $-5.35M | $-4.70M | $-4.31M | $-2.83M | $-2.53M | $-2.26M | $-2.01M | $-1.76M | $-1.49M | $-1.09M | $-602.83K | $-94.26K | $-13.46K | $-112.30K | $-336.89K | $-9.91M | $-417.39K | $-13.92M | $-58.93K | $-10.60M | $-143.16K | $-105.27K |
| Low Forecast | $-6.95M | $-6.17M | $-5.42M | $-4.97M | $-3.26M | $-2.92M | $-2.61M | $-2.32M | $-2.03M | $-1.72M | $-1.26M | $-695.73K | $-263.94K | $-15.54K | $-129.60K | $-388.81K | $-14.87M | $-417.39K | $-20.88M | $-81.52K | $-15.91M | $-198.05K | $-145.62K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 218.97% | 2761.40% | 183.17% | 35.00% | 1.76% | - | 1.09% | 213.16% | 1.20% | -38.64% | -87.30% |
2 analysts predict TARS's average Quarter EBITDA for Sep 21 to be $-13.25M, with a high of $-10.60M and a low of $-15.91M. This is -303.95% lower than Tarsus Pharmaceuticals's previous annual EBITDA (Jun 21) of $6.50M.
Tarsus Pharmaceuticals Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 3 | 3 | 1 | - | 2 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-41.90M | $-39.15M | $-21.89M | $-13.08M | $-22.51M | - | $-20.24M | $-14.85M | $-15.70M | $6.34M | $10.38M |
| Avg Forecast | $48.73M | $35.74M | $25.28M | $15.79M | $-14.37M | $-23.49M | $-23.95M | $-32.63M | $-35.46M | $-35.36M | $-34.91M | $-44.67M | $-51.90M | $-51.08M | $-36.16M | $-25.27M | $-12.19M | $-22.67M | $-17.68M | $-23.84M | $-13.04M | $15.18M | $25.53M |
| High Forecast | $51.77M | $37.96M | $26.86M | $16.78M | $-12.65M | $-20.68M | $-21.08M | $-28.72M | $-31.22M | $-30.99M | $-30.74M | $-39.33M | $-44.32M | $-44.97M | $-31.84M | $-22.25M | $-9.75M | $-22.67M | $-14.14M | $-19.23M | $-10.43M | $18.22M | $30.64M |
| Low Forecast | $42.91M | $31.46M | $22.26M | $13.91M | $-15.26M | $-24.95M | $-25.44M | $-34.66M | $-37.67M | $-38.94M | $-37.09M | $-47.45M | $-65.16M | $-54.26M | $-38.41M | $-26.84M | $-14.63M | $-22.67M | $-21.22M | $-29.34M | $-15.65M | $12.15M | $20.43M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.81% | 0.77% | 0.61% | 0.52% | 1.85% | - | 1.14% | 0.62% | 1.20% | 0.42% | 0.41% |
Tarsus Pharmaceuticals's average Quarter net income forecast for Sep 21 is $-13.04M, with a range of $-15.65M to $-10.43M. TARS's average Quarter net income forecast represents a -305.53% decrease compared to the company's last Quarter net income of $6.34M (Jun 21).
Tarsus Pharmaceuticals SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 3 | 3 | 1 | - | 2 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $43.01M | $30.32M | $15.10M | $14.63M | $11.99M | - | $7.95M | - | $6.67M | $6.79M | $5.16M |
| Avg Forecast | $372.28M | $330.62M | $290.36M | $266.49M | $174.83M | $156.46M | $139.74M | $124.50M | $108.56M | $90.86M | $67.36M | $37.28M | $11.40M | $832.42K | $6.94M | $20.83M | $7.29M | $23.44M | $10.83M | $3.89M | $11.11M | $9.44M | $6.94M |
| High Forecast | $390.13M | $346.47M | $304.29M | $279.28M | $183.21M | $163.96M | $146.44M | $130.47M | $113.77M | $96.62M | $70.59M | $39.07M | $14.82M | $872.35K | $7.28M | $21.83M | $7.64M | $23.44M | $12.76M | $4.58M | $13.08M | $11.12M | $8.18M |
| Low Forecast | $338.04M | $300.21M | $263.66M | $241.99M | $158.75M | $142.07M | $126.89M | $113.05M | $98.58M | $83.88M | $61.17M | $33.85M | $5.29M | $755.87K | $6.31M | $18.92M | $6.62M | $23.44M | $9.22M | $3.31M | $9.46M | $8.04M | $5.91M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 3.77% | 36.43% | 2.17% | 0.70% | 1.64% | - | 0.73% | - | 0.60% | 0.72% | 0.74% |
Tarsus Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $37.28M, based on 4 Wall Street analysts, with a range of $33.85M to $39.07M. The forecast indicates a -13.31% fall compared to TARS last annual SG&A of $43.01M (Dec 23).
Tarsus Pharmaceuticals EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 4 | 4 | 3 | 3 | 1 | - | 2 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | $-0.82 | $-0.53 | $-0.84 | - | $-0.98 | $-0.72 | $-0.76 | $0.31 | $0.51 |
| Avg Forecast | $1.29 | $0.94 | $0.67 | $0.42 | $-0.38 | $-0.62 | $-0.63 | $-0.86 | $-0.94 | $-0.94 | $-0.92 | $-1.18 | $-1.37 | $-1.35 | $-0.96 | $-0.67 | $-0.96 | $-0.64 | $-0.90 | $-0.75 | $-0.42 | $-0.46 | $-0.25 |
| High Forecast | $1.37 | $1.00 | $0.71 | $0.44 | $-0.33 | $-0.55 | $-0.56 | $-0.76 | $-0.83 | $-0.82 | $-0.81 | $-1.04 | $-1.17 | $-1.19 | $-0.84 | $-0.59 | $-0.85 | $-0.64 | $-0.73 | $-0.60 | $-0.34 | $-0.37 | $-0.20 |
| Low Forecast | $1.13 | $0.83 | $0.59 | $0.37 | $-0.40 | $-0.66 | $-0.67 | $-0.92 | $-1.00 | $-1.03 | $-0.98 | $-1.25 | $-1.72 | $-1.43 | $-1.02 | $-0.71 | $-1.02 | $-0.64 | $-1.11 | $-0.92 | $-0.51 | $-0.57 | $-0.31 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.86% | 0.79% | 0.88% | - | 1.08% | 0.96% | 1.82% | -0.67% | -2.03% |
According to 2 Wall Street analysts, Tarsus Pharmaceuticals's projected average Quarter EPS for Sep 21 is $-0.42, with a low estimate of $-0.51 and a high estimate of $-0.34. This represents a -234.65% decrease compared to TARS previous annual EPS of $0.31 (Jun 21).
Tarsus Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HOWL | Werewolf Therapeutics | $2.02 | $12.00 | 494.06% | Buy |
| OPT | Opthea | $2.89 | $14.00 | 384.43% | Buy |
| PEPG | PepGen | $8.83 | $29.50 | 234.09% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.22 | $7.00 | 215.32% | Buy |
| NUVB | Nuvation Bio | $2.79 | $7.00 | 150.90% | Buy |
| STOK | Stoke Therapeutics | $14.70 | $33.33 | 126.73% | Buy |
| DSGN | Design Therapeutics | $4.67 | $9.67 | 107.07% | Buy |
| PHVS | Pharvaris | $19.12 | $38.50 | 101.36% | Buy |
| TARS | Tarsus Pharmaceuticals | $30.59 | $61.00 | 99.41% | Buy |
| ETON | Eton Pharmaceuticals | $4.59 | $8.50 | 85.19% | Buy |
| TVTX | Travere Therapeutics | $10.98 | $19.50 | 77.60% | Buy |
| ALDX | Aldeyra Therapeutics | $6.13 | $10.00 | 63.13% | Buy |
| NUVL | Nuvalent | $86.25 | $107.33 | 24.44% | Buy |
| TRDA | Entrada Therapeutics | $14.80 | $18.00 | 21.62% | Buy |
| TYRA | Tyra Biosciences | $20.59 | $25.00 | 21.42% | Buy |
| CNTB | Connect Biopharma | $1.25 | $1.50 | 20.00% | Buy |
| CNTA | Centessa Pharmaceuticals | $14.30 | $15.00 | 4.90% | Hold |
| IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |
TARS Forecast FAQ
Is Tarsus Pharmaceuticals a good buy?
Yes, according to 4 Wall Street analysts, Tarsus Pharmaceuticals (TARS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of TARS's total ratings.
What is TARS's price target?
Tarsus Pharmaceuticals (TARS) average price target is $61 with a range of $61 to $61, implying a 99.41% from its last price of $30.59. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Tarsus Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for TARS stock, the company can go up by 99.41% (from the last price of $30.59 to the average price target of $61), up by 99.41% based on the highest stock price target, and up by 99.41% based on the lowest stock price target.
Can Tarsus Pharmaceuticals stock reach $50?
TARS's average twelve months analyst stock price target of $61 supports the claim that Tarsus Pharmaceuticals can reach $50 in the near future.
What are Tarsus Pharmaceuticals's analysts' financial forecasts?
Tarsus Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $285.85M (high $299.56M, low $259.56M), average EBITDA is $-10.606M (high $-9.63M, low $-11.114M), average net income is $-94.423M (high $-83.134M, low $-100M), average SG&A $595.53M (high $624.09M, low $540.76M), and average EPS is $-2.496 (high $-2.198, low $-2.652). TARS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $604.67M (high $633.68M, low $549.06M), average EBITDA is $-22.434M (high $-20.371M, low $-23.51M), average net income is $125.55M (high $133.37M, low $110.54M), average SG&A $1.26B (high $1.32B, low $1.14B), and average EPS is $3.32 (high $3.53, low $2.92).
Did the TARS's actual financial results beat the analysts' financial forecasts?
Based on Tarsus Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $17.45M, beating the average analysts forecast of $9.2M by 89.55%. Apple's EBITDA was $-143M, beating the average prediction of $-341K by 41821.21%. The company's net income was $-136M, missing the average estimation of $-139M by -2.33%. Apple's SG&A was $108.7M, beating the average forecast of $19.18M by 466.86%. Lastly, the company's EPS was $-0.0046, missing the average prediction of $-3.679 by -99.87%. In terms of the last quarterly report (Dec 2023), Tarsus Pharmaceuticals's revenue was $13.08M, beating the average analysts' forecast of $5.47M by 138.99%. The company's EBITDA was $-44.45M, beating the average prediction of $-203K by 21796.88%. Tarsus Pharmaceuticals's net income was $-41.902M, missing the average estimation of $-51.897M by -19.26%. The company's SG&A was $43M, beating the average forecast of $11.4M by 277.28%. Lastly, the company's EPS was $-0.0013, missing the average prediction of $-1.372 by -99.91%